HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series
In this latest webinar, Dr.
HTG also provided a real-world example of how its team has used RNA profiling to differentiate between several compounds targeting mTOR in development of its transcriptome-informed approach to drug discovery. This study has allowed the team to specifically describe differential regulation of the ferroptosis pathway by closely related compounds. Ferroptosis is an alternative cell-death pathway, and its regulation represents a promising cancer therapy target.
The webinar is available on-demand at the following link: REGISTER.
HTG's Therapeutics unit is actively using its transcriptome-informed approach to drug discovery to design and further refine small-molecule chemical libraries. The goal of this approach is to enable the selection and characterization of de-risked candidate molecules across selected therapeutic targets of interest leading to potential business development and licensing opportunities in various therapeutic areas. A video providing an overview of HTG’s Therapeutics business, white papers and additional materials are available on the Company’s website HERE.
About KOL Dr. Spitale:
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities and benefits of using RNA profiling in the drug discovery process, results that may be implied from prior results, the goals of HTG transcriptome-informed drug discovery approach and the ability to achieve those goals, and the design and potential benefits, including potential scalability, of HTG’s RNA platform technologies. Words such as “believes,” “plans,” “can,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with drug discovery and development; past results may not be indicative of future results; the risk that our RNA platform and medicinal chemistry technologies may not provide the benefits that we expect; risks associated with our ability to develop and commercialize our products; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; risks associated with the impact of the COVID-19 pandemic on us and our customers; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission (SEC), including under the “Risk Factors” heading of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, as filed with the SEC on November 10, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made
Phone: (617) 430-7577
Source: HTG Molecular Diagnostics, Inc.